Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases.
Ratings
0 / 5
0 ratings in the last 12 months
5
4
3
2
1
CEO
Dr. David D. Chang, M.D.,PhD$595.2M
Market Cap • 17/04/20242017
(há 7 anos)
2018
(6 years ago)
NASDAQ
Listagem
South San Francisco
Sede • California361
N° de Empregados • 2022Valuation
Company FinancialsValuation Indicators
Valuation IndicatorsRetorno Histórico
ALLOSó no Premium...
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.